SNPHY Santen Pharmaceutical Co Unsp/Adrs
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase 2b clinical trial; DE-128 in Europe, as well as is in Phase 2/3 clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase 3 clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase 2/3 clinical trial in Japan, as well as is in Phase 3 in Asia; and MD-16 for the treatment of cataract. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan. This is an ADR of a company whose stock trades outside of the U.S. as the symbol JT:4536.
This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.
$8.27 Pink
As of 03/23/2023 OTCMarkets
Security Information
Category1: US Equity
Category2: ADRs
Category3: Mid cap
GICS sector: Health Care
Industry: Drug Manufacturers-General
Index country: Japan
Country of incorporation: Japan
IPO date: 11/30/2018
Outstanding shares: 388,231,854
Average volume: 5,960
Market cap: $3,208,736,273
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Quarterly filings: 10-Q
Annual filings: 10-K
Sedol:
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%